| Camu Camu (Myrciaria dubia) — An Amazonian fruit from the Myrtaceae family, native to the Amazon basin of South America. Classified as a polyphenol-rich food source and functional food, commonly abbreviated CC. It contains exceptionally high concentrations of vitamin C (ascorbic acid), ellagitannins including castalagin, ellagic acid derivatives, flavonols, anthocyanins, and proanthocyanidins. Its most therapeutically distinctive property is microbiome-mediated immunomodulation, with preliminary evidence of enhanced immune checkpoint inhibitor efficacy. It is not an approved anticancer treatment.
Camu Camu - Active Ingredients and Constituents
| Rank |
Ingredient / Constituent |
Class |
Reported Content |
Primary Biological Relevance |
Notes |
| 1 |
Castalagin |
Ellagitannin |
Not individually quantified; included in total ellagitannins of 16.10 mg/100 g dried pulp |
Gut microbiome modulation; enhanced anti-PD-1 response |
Highest mechanistic relevance for cancer immunotherapy. |
| 2 |
Vitamin C (Ascorbic acid) |
Vitamin |
1,889-4,752 mg/100 g pulp in selected studies; 3,510 mg/100 g spray-dried pulp |
Antioxidant activity, collagen synthesis, immune support |
High natural concentration; varies with maturity, storage and processing. |
| 3 |
Vescalagin |
Ellagitannin |
Not individually quantified; part of 16.10 mg/100 g ellagitannins in dried pulp |
Polyphenol-related antioxidant and potential microbiome effects |
Structurally related to castalagin. Separate clinical contribution uncertain. |
| 4 |
Ellagic acid |
Phenolic acid derivative |
5.60 mg/100 g spray-dried pulp; substantially higher values reported in other preparations |
Antioxidant, anti-inflammatory and experimental anticancer mechanisms |
Partly metabolized by intestinal bacteria into urolithins. |
| 5 |
Proanthocyanidins |
Polyphenol class |
1,855 mg/100 g dry extract in one study; 35.77 mg/100 g in a seed preparation |
Antioxidant and intestinal microbial interactions |
Concentration strongly dependent on fruit fraction and extraction. |
| 6 |
Quercetin |
Flavonol |
33.5 mg/100 g dry extract; 0.9 mg/100 g in a peel/seed preparation |
Anti-inflammatory signaling and experimental anticancer activity |
Free quercetin and glycosides contribute to total content. |
| 7 |
Myricetin |
Flavonol |
74.3 mg/100 g dry extract; 2.1 mg/100 g in a peel/seed preparation |
Antioxidant and experimental regulation of cancer-associated signaling |
Occurs as free myricetin and glycosides. |
| 8 |
Anthocyanins |
Flavonoid pigments |
19.63 mg/100 g spray-dried pulp; up to 170 mg/100 g reported in other pulp samples |
Antioxidant, vascular and inflammatory modulation |
Predominantly associated with pigmented peel and ripe fruit. |
| 9 |
Cyanidin-3-O-glucoside |
Anthocyanin |
182.56 mg/100 mL reported in one preparation |
Antioxidant and experimental inflammatory regulation |
Major identified anthocyanin; specific sample composition matters. |
| 10 |
Delphinidin-3-O-glucoside |
Anthocyanin |
Not consistently quantified |
Antioxidant and experimental cell-signaling effects |
Identified in fruit pigment profile. |
| 11 |
Catechins |
Flavan-3-ols |
12.4 mg/100 g catechin reported in peel/seed material |
Antioxidant and polyphenol-mediated signaling |
Link is to the database's catechin class. |
| 12 |
Epicatechin |
Flavan-3-ol |
Detected; representative content not established |
Antioxidant and potential vascular effects |
Present in phytochemical profiling. |
| 13 |
Gallic acid |
Phenolic acid |
Detected; representative content not established |
Antioxidant, anti-inflammatory and experimental anticancer signaling |
Also contributes structurally to hydrolysable tannins. |
| 14 |
Rutin |
Flavonol glycoside |
Detected; representative content not established |
Antioxidant and vascular signaling |
Minor constituent; not a principal standardized marker. |
| 15 |
Luteolin |
Flavone |
Detected; representative content not established |
Inflammatory and experimental anticancer signaling |
Minor reported phenolic constituent. |
| 16 |
Lutein |
Carotenoid |
0.602 mg/100 g fruit in one carotenoid profile |
Antioxidant and retinal protection |
Major identified carotenoid in the cited profile. |
| 17 |
Beta-carotene |
Carotenoid |
0.142 mg/100 g fruit in one profile |
Provitamin A, antioxidant activity |
Modest concentration relative to vitamin C. |
| 18 |
Violaxanthin |
Xanthophyll |
0.116 mg/100 g fruit in one profile |
Carotenoid antioxidant activity |
Minor constituent. |
| 19 |
Alpha-linolenic acid |
Omega-3 fatty acid |
Detected; representative content not established |
Essential fatty acid and lipid metabolism |
Not a concentrated dietary source. |
| 20 |
Potassium |
Mineral |
Variable; preparation-dependent |
Electrolyte balance |
Ordinary nutritional constituent. |
| 21 |
Calcium |
Mineral |
Variable; preparation-dependent |
Bone and cellular signaling |
Not considered a major calcium source. |
| 22 |
Magnesium |
Mineral |
Variable; preparation-dependent |
Enzyme and energy metabolism |
Minor nutritional contribution. |
Quantification note: Values refer to different published analytical samples and are not additive. Fresh pulp, spray-dried pulp, concentrated dry extract, peel and seeds differ substantially. Total class measurements include individual constituents already listed and must not be added to them. ND or unreported individual quantities have not been assigned estimated values.
Database note: Linked ingredients correspond to existing Nestronics products. Castalagin is the highest-priority proposed new compound. Camu camu itself is currently listed under Probiotic in the product index, although Food Source is a more appropriate classification for the fruit.
Primary mechanisms (ranked):
- Gut microbiome modulation: Castalagin interacts with intestinal bacteria, particularly Ruminococcus species, and promotes microbial communities associated with favorable antitumor immune responses. This prebiotic-like mechanism is central to its investigated anticancer effects.
- Immune checkpoint sensitization: In preclinical cancer models, camu camu and castalagin improve responses to anti-PD-1 therapy, increase the intratumoral CD8+/FOXP3+CD4+ T-cell ratio, and partially overcome microbiome-associated immunotherapy resistance.
- Microbial metabolite modulation: Alters gut-derived metabolic signaling, including taurine-conjugated bile acids, potentially contributing to systemic immunological effects.
- Inflammatory signaling modulation: Human studies demonstrate reductions in circulating inflammatory markers including CRP, IL-6, and IL-8. The effects depend on the population, formulation, and treatment context.
- Oxidative stress reduction: Vitamin C and phenolic constituents contribute antioxidant activity, with reduced oxidative stress biomarkers demonstrated in a small human randomized study. ROS modulation is a secondary mechanism rather than the primary explanation for checkpoint sensitization.
- Gut-liver metabolic regulation: Polyphenol-associated microbiome changes may improve hepatic lipid metabolism. A small randomized crossover trial demonstrated reductions in liver fat and liver injury markers.
Bioavailability / PK relevance: Oral delivery is appropriate for its principal gut-mediated activity; high systemic absorption of castalagin is not necessarily required. Ellagitannin metabolism is influenced by intestinal microbiota and may differ substantially among individuals. Vitamin C absorption is saturable, and anthocyanins and other polyphenols exhibit variable systemic bioavailability. Whole-fruit powder, pulp powder, juice, and concentrated extracts are not compositionally interchangeable. Castalagin content and microbiome effects cannot be assumed equivalent across commercial products.
In-vitro vs systemic exposure relevance: The leading anticancer mechanism is largely dependent on intestinal microbial interactions and downstream immune responses rather than direct tumor exposure to high concentrations of camu camu phytochemicals. Concentrations used in cell-culture experiments with isolated phenolics or extracts may exceed achievable circulating concentrations. Such experiments should not be interpreted as evidence of direct systemic cytotoxicity following ordinary dietary consumption.
Clinical evidence status: Preclinical mechanistic evidence; small human RCTs; investigational cancer adjunct. In a randomized phase I study of 31 patients with metastatic renal cell carcinoma, camu camu 1,500 mg/day added to nivolumab/ipilimumab was associated with longer median progression-free survival (16.4 vs 5.4 months), but the prespecified Ruminococcus enrichment endpoint was not significantly achieved and immune-related toxicities were observed. Separate human RCTs report improvements in oxidative stress biomarkers and liver fat. Anticancer efficacy remains preliminary, without confirmatory phase III evidence.
Safety / clinical limitations: Food-level consumption is generally distinct from concentrated supplementation. Acidic preparations and high vitamin C exposure may cause gastrointestinal intolerance; excessive vitamin C intake can be problematic in individuals susceptible to oxalate kidney stones or with iron-overload disorders. Importantly, the 2026 immunotherapy trial reported cerebritis, immune thrombocytopenia, and adrenal insufficiency in the camu camu combination arm. Causality has not been established, but unsupervised use alongside checkpoint inhibitors is not advisable.
Camu Camu Mechanistic Effects
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Gut Microbiome / Castalagin / Ruminococcus |
↓ Tumor progression (model-dependent) |
↑ Beneficial microbial interactions |
G |
Microbiome-mediated antitumor modulation |
Castalagin interacts with Ruminococcus bromii; microbial community shifts and treatment responses are microbiome-dependent. Human enrichment of Ruminococcus was not uniformly reproduced. |
| 2 |
Anti-PD-1 Immunotherapy Sensitization |
↓ Immune escape (model-dependent) |
↑ Antitumor immune activity |
G |
↑ Checkpoint inhibitor responsiveness |
Preclinical rescue of anti-PD-1 resistance; preliminary randomized phase I clinical signal in metastatic renal cell carcinoma. Not established as a standard adjunct. |
| 3 |
CD8+ T Cells / FOXP3+ Regulatory T Cells |
↑ Immune-mediated tumor control |
↑ CD8+/FOXP3+CD4+ ratio in tumor microenvironment |
G |
Improved antitumor immune balance |
Reported in mouse tumor models. Does not establish selective direct toxicity against malignant cells. |
| 4 |
Microbial Bile Acid Metabolism |
↔ Indirect (context-dependent) |
↑ Taurine-conjugated bile acids (model-dependent) |
G |
Microbiome-derived metabolic signaling |
Castalagin-associated bile acid changes may contribute to immune regulation; precise causal contribution remains uncertain. |
| 5 |
Inflammation / IL-6 / IL-8 / CRP |
↔ Context-dependent |
↓ IL-6, IL-8, CRP in a small human trial |
G |
Systemic anti-inflammatory activity |
Human smoker study found reduced biomarkers after seven days. The immunotherapy trial showed ↓ IL-8 but ↑ IL-10 and IL-17A; inflammatory effects are not uniformly suppressive. |
| 6 |
ROS / Oxidative DNA Damage |
↔ Context-dependent |
↓ ROS and urinary 8-OHdG |
G |
Reduced oxidative stress biomarkers |
Secondary antioxidant activity supported by a small human trial. Antioxidant responses should not be equated with cancer-cell killing or proven NRF2 activation. |
| 7 |
Hepatic Lipid Accumulation / Gut-Liver Axis |
↔ Not established |
↓ Hepatic fat, ALT and AST |
G |
Metabolic and hepatoprotective activity |
A 30-participant randomized crossover study found improvement with 1.5 g/day over 12 weeks. This is metabolic evidence, not proof of anticancer hepatoprotection. |
| 8 |
Clinical Translation Constraint |
↔ Variable tumor response |
↔ Variable tolerability and immune effects |
G |
Formulation, microbiome, and immunotoxicity limitations |
Variable castalagin content, interindividual microbiome differences, limited clinical sample sizes, uncertain long-term outcomes, and serious immune-related adverse events during combination immunotherapy. |
TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr
|